Navigation Links
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
Date:2/18/2009

e (pCR) rate and the results of the MammaPrint(R) test. The achievement of pCR is a valuable indicator for long-term response in this clinical setting. A consecutive series of 167 patients who received neoadjuvant chemotherapy for stage II or III breast cancer was analyzed to assess MammaPrint's predictive power. 20 percent of the 144 patients in the high risk group achieved a pCR, whereas none of the patients in the low risk group achieved a pCR. After a median follow-up of 25 months, 17 relapses were seen in the high risk group and none in the low risk group. These findings demonstrate that tumors with a high risk MammaPrint(R) signature are sensitive to chemotherapy.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-certified service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's t
'/>"/>

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ANGELES , July 6, 2015 ImmunoCellular ... establishment of an agreement with Novella Clinical ... ICT-107 in patients with newly diagnosed glioblastoma. Novella is ... trial services to small to mid-sized oncology companies. The ... sites in the US, Europe ...
(Date:7/3/2015)... ... July 03, 2015 , ... The ... companies and professional service industries alike-- typically known for its consummate professionalism-- embarks ... a good cause and break from their day jobs. , "Our motto has ...
(Date:7/3/2015)... YORK , July 3, 2015  Pomerantz LLP ... against Puma Biotechnology, Inc. ("Puma" or the "Company")(NYSE: ... action, filed in United States District Court, Central District ... 15-cv-00865, is on behalf of a class consisting of ... July 23, 2014 and May 13, 2015 inclusive (the ...
(Date:7/2/2015)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today announced a litigation update. In ... Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in the ... Virginia , the Court issued a ... claims in favor of the Defendants on the one ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) ... announced,today a definitive agreement for Abbott to acquire AMO for ... approximately $2.8 billion, inclusive,of estimated net debt at the time ... global leader in ophthalmic care, comprised of three segments: cataract,surgery, ...
... 12 Bavarian Nordic,owns several United States patents ... technology, MVA-BN(R), which is the basis for its ... vector for delivering,recombinant vaccines. Bavarian Nordic has asserted ... action. The claim in this case is that ...
... Hainan, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- China,Pharma ... CPHI), which,develops, manufactures, and markets specialty pharmaceutical ... Food and Drug Administration ("SFDA"),approved the production ... in the National Medical Insurance Program, thus ...
Cached Biology Technology:Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules 2China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules 3
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... ingredient in the venom of the "deathstalker" scorpion could help ... are reporting. The substance allows therapeutic genes genes that ... current approaches, according to the study in ACS Nano ... that gene therapy the delivery of therapeutic genes into ...
... gallons of oil still in the Gulf of Mexico from ... that consume oil and other hydrocarbons and could break down ... an article in the current issue of Chemical & ... out that the oil-eating bacteria are beneficial in helping to ...
... causes and effects of hypoxia in Green Bay, part of ... year of an anticipated four-year $1,367,300 project through NOAA,s Coastal ... problem for decades, and recent evidence suggests that it may ... kills to become both more frequent and more extensive with ...
Cached Biology News:NOAA awards grant to investigate impacts of land use and climate change on hypoxia in Green Bay 2
... familiar interface for data capture, recording, ... transition from paper to this powerful ... contains an integrated LIMS, notary service, ... These functions allow LABTrack to achieve ...
High voltage electrophoresis power supply...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Biology Products: